Exagen Inc. · NASDAQ:XGN
Exagen — Investor Presentation (January 2022)
17 slides from Exagen's investor presentation, Jan 10, 2022
Slide 1: Rheumatoid Arthritis Drug Response
EXAGEN CONFIDENTIAL1 Rheumatoid Arthritis Drug Response
Slide 2: Forward-Looking Statements
This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, , current and future product offerings, including
Slide 3: Precision Medicine for Rheumatoid Arthritis
EXAGEN CONFIDENTIAL3 Unmet Need Currently, 70%–80% of RA patients fail to reach low disease activity2 Innovative Platform First rule-in therapy selection test for rheumatoid arthritis Exclusive Rights Exagen holds the exclusive worldwide license to the IP rights Minimally Invasive Synovial tissue is
Slide 4: Significant Unmet Needs
Significant Unmet Needs EXAGEN CONFIDENTIAL4
Slide 5: Low Patient Response Rates
Low Patient Response Rates EXAGEN CONFIDENTIAL5 Do NOT achieve an ACR20 response Do NOT achieve an ACR50 response Do NOT achieve an ACR70 response References: Pitzalis et al. Nature Reviews Rheumatology. 2020. 40% 60% 80% *ACR response rates include all RA therapeutics
Slide 6: Large Addressable Market
Large Addressable Market EXAGEN CONFIDENTIAL6 $18B in Wasted RA Therapeutic Spend Existing patients in the U.S. living with RA1 ~2 Million 70%-80% RA patients fail to reach low disease activity3 References: 1. Myasoedova et al. Arthritis & Rheumatology 2010 2. IQVIA DDD Data; IBM Truven patient clai
Slide 7: Precision Medicine Approach Helps Guide Treatment
Precision Medicine Approach Helps Guide Treatment EXAGEN CONFIDENTIAL7
Slide 8: A Formula for RA Precision Medicine
A Formula for RA Precision Medicine Clinical disease activity indices EXAGEN CONFIDENTIAL8 An ‘Individual Patient Signature’ is based on the following features: References: Ribera et al. Annals of Rheumatic Diseases. 2019. Gene expression analysis performed on synovial tissue Proteomics RA lab test
Slide 9: The AVISE RADR Approach to Personalized Medicine
The AVISE RADR Approach to Personalized Medicine 1. Synovial Biopsy Patients undergo a minimally invasive procedure to collect 6 biopsies in one visit 2. Gene Expression Profiling Performed on synovial tissue collected from an affected joint; pathotype is determined 3. Personalized Medicine The pati
Slide 10: Rheumatoid Arthritis Pathotypes
Rheumatoid Arthritis Pathotypes EXAGEN CONFIDENTIAL10 References: Lewis et al. Cell Reports. 2019; Kelly et al. Ann Rheum Dis. 2015 RA pathotypes are defined by the type of immune cells present in affected joints H&E CD3 CD20 CD68 CD138 Lympho-myeloid Diffuse-myeloid Pauci-immune fibroid
Slide 11: Synovial Biopsy is Superior to Other Methods
Synovial Biopsy is Superior to Other Methods EXAGEN CONFIDENTIAL11 References: Lewis et al. Cell Reports. 2019; Kelly et al. Ann Rheum Dis. 2015 differently expressed transcripts in blood 8 3,000 differently expressed transcripts in synovial tissue
Slide 12: The Value of Precision Medicine
The Value of Precision Medicine EXAGEN CONFIDENTIAL12 Once a patient fails to respond, a doctor has 12 drugs to choose from, with no current rule-in test to guide their decision. Existing Patient Journey1 AVISE RADR Patient Journey Speed and accuracy in the treatment selection has the potential to p
Slide 13: AVISE RADR Position in the Patient Journey
AVISE RADR Position in the Patient Journey EXAGEN CONFIDENTIAL13 RA diagnosis csDMARD therapy Disease managed adequately Disease inadequately managed 1st line therapy 2nd line therapy 1 2 Patient most likely to respond to anti-TNF therapy Patient most likely to respond to B-cell depleting therapy Pa
Slide 14: AVISE RADR expands our well-respected and proven portfolio
AVISE RADR expands our well-respected and proven portfolio Owning the Hilltop EXAGEN CONFIDENTIAL14
Slide 15: Exagen is a Leader in Rheumatology
Exagen is a Leader in Rheumatology Minimally invasive Uses existing equipment Replaces the issues with rule-out empirical treatments with precision personalized medicine EXAGEN CONFIDENTIAL15 Exagen has a highly respected rheumatology salesforce in place with support and infrastructure ready to go W
Slide 16: Precision Medicine for Rheumatoid Arthritis
EXAGEN CONFIDENTIAL16 Unmet Need Currently, 70%–80% of RA patients fail to reach low disease activity2 Innovative Platform First rule-in therapy selection test for rheumatoid arthritis Exclusive Rights Exagen holds the exclusive worldwide license to the IP rights Minimally Invasive Synovial tissue i
Slide 17: Thank You
Thank You